about
Understanding the experience and manifestation of depression in people living with HIV/AIDS in South Africa.Impact of the HIV Tat C30C31S dicysteine substitution on neuropsychological function in patients with clade C disease.Task sharing of a psychological intervention for maternal depression in Khayelitsha, South Africa: study protocol for a randomized controlled trialGenerating evidence to narrow the treatment gap for mental disorders in sub-Saharan Africa: rationale, overview and methods of AFFIRM.Maladaptive coping mediates the influence of childhood trauma on depression and PTSD among pregnant women in South Africa.Implementation of Cognitive-Behavioral Substance Abuse Treatment in Sub-Saharan Africa: Treatment Engagement and Abstinence at Treatment ExitImproving mental health among people living with HIV: a review of intervention trials in low- and middle-income countriesExploring the utility of the Montreal Cognitive Assessment to detect HIV-associated neurocognitive disorder: the challenge and need for culturally valid screening tests in South Africa.Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence.Applying the HIV-associated neurocognitive disorder diagnostic criteria to HIV-infected youthIncreases in CSF dopamine in HIV patients are due to the dopamine transporter 10/10-repeat allele which is more frequent in HIV-infected individuals.Poverty and common mental disorders in low and middle income countries: A systematic review.Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled trial of lithium.Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.The neurobiology of HIV dementia: implications for practice in South Africa.Integrating mental health into general health care: lessons from HIV.Severe mental illness and retention in anti-retroviral care: a retrospective study.Executive Dyscontrol of Learning and Memory: Findings from a Clade C HIV-positive South African Sample.HIV/AIDS and mental health research in sub-Saharan Africa: a systematic review.Adding a brief self-report cognitive tool to the IHDS improves effectiveness of identifying patients with HIV-associated dementia in South Africa.Simulating therapeutic drug monitoring results for dose individualisation to maintain investigator blinding in a randomised controlled trialImpact of Sexual Trauma on HIV Care Engagement: Perspectives of Female Patients with Trauma Histories in Cape Town, South Africa.Sensitivity and specificity of clinician administered screening instruments in detecting depression among HIV-positive individuals in Uganda.Does screening HIV-positive individuals in Uganda for major depressive disorder improve case detection rates and antidepressant prescription?A pilot study of a nurse-delivered cognitive behavioral therapy intervention (Ziphamandla) for adherence and depression in HIV in South AfricaQuantitative proteomic analysis of HIV-1 Tat-induced dysregulation in SH-SY5Y neuroblastoma cells.Beyond methamphetamine: Documenting the implementation of the Matrix model of substance use treatment for opioid users in a South African setting.Escitalopram treatment of depression in human immunodeficiency virus/acquired immunodeficiency syndrome: a randomized, double-blind, placebo-controlled study.Topological Organization of Whole-Brain White Matter in HIV Infection.The dopamine-related polymorphisms BDNF, COMT, DRD2, DRD3, and DRD4 are not linked with changes in CSF dopamine levels and frequency of HIV infection.Neuroimaging abnormalities in clade C HIV are independent of Tat genetic diversity.HIV Infection Is Associated with Impaired Striatal Function during Inhibition with Normal Cortical Functioning on Functional MRI.Prefrontal cortical thinning in HIV infection is associated with impaired striatal functioning.A Comparison of Five Brief Screening Tools for HIV-Associated Neurocognitive Disorders in the USA and South Africa.White matter micro-structural changes in ART-naive and ART-treated children and adolescents infected with HIV in South Africa.Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.Clinical associations of white matter damage in cART-treated HIV-positive children in South Africa.HIV Risk Behavior Among Methamphetamine Users Entering Substance Abuse Treatment in Cape Town, South Africa.Resting-state functional magnetic resonance imaging in clade C HIV: within-group association with neurocognitive function.Proposed Training Areas for Global Mental Health Researchers.
P50
Q34562047-5186AC4D-F563-44A9-B508-ACF1D0B91DD5Q34714684-0F565522-1958-47C6-A166-9E94EA3D5C23Q34898067-B4C62FCC-598C-4F20-8EFD-A747BD32DD55Q35817966-B059AC98-5827-459F-BBDE-718E020C205EQ35847011-2A6B58FD-6958-4EBF-ACA5-96130A955F12Q35905745-63C48485-17ED-4514-9C8A-6662C2D7B98BQ36110015-7C4F8F17-156D-4416-A98A-9E5C5CFB28DFQ36781217-FB6224F3-FABA-4A6C-AB67-4A98C0255AD8Q36940756-CAB6FBED-3D19-40BA-A560-523DD060A4C0Q37063463-B0350D76-3942-455B-9DE0-086164C83566Q37188241-70B53C48-6407-4448-A0A7-291034B24650Q37191017-CB49C5C8-0048-4A2C-B0EC-6D8408C9147EQ37433079-6A9DB9A7-DC2A-47C3-962A-9BCA5A809DEAQ37624865-D7A34D9A-6D09-4BD0-9BE7-C08A8E4BC1CEQ37867525-611C17AD-1566-4FEA-8874-8F64CE1D34A1Q38060546-D22061FA-A2FC-4330-B26E-197D4D87D309Q38187035-508D8C7D-097A-4594-8C16-601FAF4EB559Q38400463-95609AC8-0D0B-4242-846E-29C8CE6B020FQ38414099-6E357A85-CDA2-4B3B-BFED-C8FECC2A3A8CQ38658460-8E94D2BE-2E0D-4272-B2C8-A30B2A362318Q38737750-186ADE4A-36F1-40F8-AC55-7D52D727D3E5Q38793188-63D21587-71FC-441E-931B-96D788806307Q38866035-0D035FA0-4254-473E-9298-78FD5DD61B76Q38866521-8A087211-6D39-4EB8-871A-9B6C1181395FQ38874883-077B8E57-974E-4BCA-839A-3963B8D8605AQ39013171-2F44A78F-125E-4E9D-84BA-7437B4017C25Q39111855-6FA33095-1A1A-4B40-945A-DAB313A97837Q39262518-941E097C-DCA0-4FD5-AFB7-59C259814669Q40376382-80F47C4B-DB36-4741-9E17-DC3FC9723F58Q40426768-BE31DC63-4012-45D2-B15E-2522FA4300D7Q40443793-5F31D21E-1785-464F-BD6B-664E1B56D4BDQ40468655-919B397D-3374-421A-8804-C33E99B6E0E6Q40676918-F52E8A15-70CB-4810-9F78-BC90E3DCA059Q40798405-5F3BA403-5E5A-47E5-A496-050B387FDA79Q40998814-E40FDE6F-C0A8-4747-A680-E71964BC5BA9Q41208022-894A1CBB-8DB9-48CF-A1AE-E43DDF41D8E7Q41532229-291571A3-EF8F-42F6-A9F1-AB702FA231F7Q41629143-2C9F05E9-F18F-405B-A769-5016832A624BQ41925787-B3DD8409-5D5F-4146-9482-662D3AD1D836Q41978981-AFCC850E-71A0-410B-9BEE-13D381F58AB4
P50
description
investigador
@es
researcher
@en
name
John A Joska
@en
type
label
John A Joska
@en
prefLabel
John A Joska
@en
P31
P496
0000-0003-4260-1181